Clinical trial · Observational
Sialic Acid in Hepatocellular Carcinoma
Serum Sialic Acid as a Novel Biomarker in the Diagnosis of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma (HCC) accounts for approximately 90% of the cases of liver cancer and is associated with high morbidity and mortality. The increased sialic acids(SAs) in tumor cells are mainly caused by the special metabolic flux and aberrant expression of sialyltransferases/sialidases, The high sensitivity of sialic acids in or plasma as a tumor marker has been reported in various cancerous conditions the level of sialic acid(SA) activity was found to offer highly specific and sensitive tumor biomarker for diagnosis and follow up of HCC post-therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum sialic acid | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- healthy persons
- description
- The study group will include normal healthy persons who will be selected randomly.
- interventionNames
- Diagnostic Test: serum sialic acid
- label
- cirrhotic patients
- description
- The study group will include patients diagnosed with liver cirrhosis with no detected hepatic focal lesion by ultrasound.
- interventionNames
- Diagnostic Test: serum sialic acid
- label
- cirrhotic patients with hepatocellular carcinoma
- description
- The study group will include patients with liver cirrhosis and hepatocellular carcinoma. All causes of liver cirrhosis will be accepted. HCC will be assessed by triphasic CT or MRI.
- interventionNames
- Diagnostic Test: serum sialic acid
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * The study will include normal persons, patients with liver cirrhosis and HCC patients attending to the outpatient clinic or inpatient section of the department of Tropical medicine and Gastroenterology and Radiological department at Sohag University Hospital will be included. Exclusion Criteria: * 1- Patients aged \< 18 or \> 70 years. 2- Patients with other malignancy rather than HCC. 3- Patients with history of prior intervention or systemic chemotherapy for HCC.
References
Publications (0)
Data not yet available